JP2010520185A - ブプレノルフィンとナロキソンを含む改良医薬組成物 - Google Patents
ブプレノルフィンとナロキソンを含む改良医薬組成物 Download PDFInfo
- Publication number
- JP2010520185A JP2010520185A JP2009551255A JP2009551255A JP2010520185A JP 2010520185 A JP2010520185 A JP 2010520185A JP 2009551255 A JP2009551255 A JP 2009551255A JP 2009551255 A JP2009551255 A JP 2009551255A JP 2010520185 A JP2010520185 A JP 2010520185A
- Authority
- JP
- Japan
- Prior art keywords
- buprenorphine
- naloxone
- composition
- pain
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- SFNLWIKOKQVFPB-KZCPYJDTSA-N bunavail Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C.C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 SFNLWIKOKQVFPB-KZCPYJDTSA-N 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 229960001736 buprenorphine Drugs 0.000 claims abstract description 45
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 229960004127 naloxone Drugs 0.000 claims abstract description 35
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims abstract description 35
- 208000002193 Pain Diseases 0.000 claims abstract description 19
- 230000036407 pain Effects 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 16
- 230000036592 analgesia Effects 0.000 claims abstract description 8
- 239000002552 dosage form Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000000202 analgesic effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000002411 adverse Effects 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229940005483 opioid analgesics Drugs 0.000 description 6
- 239000003826 tablet Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000003502 anti-nociceptive effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000003887 narcotic antagonist Substances 0.000 description 3
- 239000003402 opiate agonist Substances 0.000 description 3
- 230000037325 pain tolerance Effects 0.000 description 3
- 239000004031 partial agonist Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 206010038678 Respiratory depression Diseases 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 239000003401 opiate antagonist Substances 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229960004088 naloxone hydrochloride dihydrate Drugs 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229940121367 non-opioid analgesics Drugs 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
以下の組成:
を有する舌下錠を、ステアリン酸マグネシウムを除く全ての材料を750μmの篩に通す篩過と、これらの材料の混合により調製した。次に、混合した粉末を湿式造粒(aqueous granulation)処理に供し、50℃で乾燥させた。得られた顆粒を750μmの篩に強制的に通し、ステアリン酸マグネシウム(事前に500μmの篩に篩過させてある)と混合した。錠剤用の顆粒を圧縮して、直径5.56mm、質量60mgの錠剤を得た。
コールドプレッサー(cold pressor:CP)試験を用いて、ブプレノルフィン、ブプレノルフィンとナロキソンとの組み合わせの抗侵害受容を評価した。ブプレノルフィン、ブプレノルフィンとナロキソンとの組み合わせは、(典型的には数分後に)加速させようとすることなく溶解又は分散されるようにと舌下で錠剤を保持することにより投与された。CP試験を投与完了から約20分後に開始し、その後1時間間隔で継続した。化合物の形態は、塩酸ブプレノルフィン及びナロキソン塩酸塩二水和物であった。CP試験では、2つのプラスチック製の円筒形容器を用い、一方を温水で満たし、もう一方を水と砕いた氷とを組み合わせたもので満たして“雪解け状態(slushy)”にした。被験者は、利き手ではないほうの前腕と手を温水にちょうど2分間浸した。1分45秒の時点で、浸した腕に装着した血圧測定器のカフを、拡張期血圧から20mmHg下の圧力にまで膨らませた。血圧測定器のカフにより、低温に対する反応を調べるにあたって、血流の役割が最小限に抑えられた。ちょうど2分の時点で、前腕を温水から冷水に移動させた。全手順を通して被験者の両眼を覆うことにより、被験者が注意散漫となったり時間の見当をつけてしまうことを最小限に抑えた。前腕を冷水に浸した際、被験者には、最初に痛みを感じた時点で知らせるようにと依頼し(痛覚閾値、CPTHR)、次に、痛みにそれ以上耐えられなくなるまで腕を浸したままにするよう依頼した(疼痛耐性、CPTOL)。疼痛閾値及び耐容時間を、冷水に浸してから秒単位で記録した。被験者には非通知の180秒のカットオフ時間で冷水浴を打ち切った。180秒を越えると、しびれ感から疼痛耐性がもはや正確には評価できないからである。疼痛耐性(CPTOL)は、現在の調査において報告される疼痛応答パラメータである。
Claims (10)
- 患者の痛みを治療するための組成物であって、ブプレノルフィンとナロキソンとを痛覚脱失を得るのに適した量であるブプレノルフィン対ナロキソンの質量比2.1:1〜8:1で含み、経皮又は経粘膜剤形にあることを特徴とする組成物。
- 前記比が2.5:1〜6:1、好ましくは3:1〜5:1、好ましくは3.5:1〜4.5:1である、請求項1に記載の組成物。
- 投与単位あたりのブプレノルフィン量が10μg〜8mgである、請求項1に記載の組成物。
- 前記組成物を口腔・鼻腔投与用に適合させる、請求項1に記載の組成物。
- 患者の痛みを治療するための方法であって、患者にブプレノルフィンとナロキソンとをブプレノルフィン対ナロキソンの質量比2.1:1〜8:1の範囲で経皮又は経粘膜投与することを含むことを特徴とする方法。
- 舌下投与を含む、請求項5に記載の方法。
- 患者の痛みを治療するための薬物の製造におけるブプレノルフィン及びナロキソンの使用であって、前記薬物は経皮又は経粘膜投与用であり、ブプレノルフィン及びナロキソンは、ブプレノルフィン対ナロキソンの質量比2.1:1〜8:1で前記薬物に配合されることを特徴とする使用。
- 前記投与は典型的には1分〜10分続く、請求項5、6又は7に記載の方法又は使用。
- ブプレノルフィンの投与が、24時間あたり体重1kgにつき0.25μg〜640μgの範囲でなされる、請求項5、6、7又は8に記載の方法又は使用。
- 実質的に本発明に従って前述したような組成物又は方法又は使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0703967A GB2447015A (en) | 2007-03-01 | 2007-03-01 | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
PCT/GB2008/000523 WO2008104737A1 (en) | 2007-03-01 | 2008-02-15 | Improved medicinal compositions comprising buprenorphine and naloxone |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010520185A true JP2010520185A (ja) | 2010-06-10 |
JP2010520185A5 JP2010520185A5 (ja) | 2011-03-31 |
Family
ID=37965734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009551255A Ceased JP2010520185A (ja) | 2007-03-01 | 2008-02-15 | ブプレノルフィンとナロキソンを含む改良医薬組成物 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100168147A1 (ja) |
EP (1) | EP2114453A1 (ja) |
JP (1) | JP2010520185A (ja) |
KR (1) | KR20090115863A (ja) |
CN (2) | CN102670610A (ja) |
AR (1) | AR065581A1 (ja) |
AU (1) | AU2008220573A1 (ja) |
BR (1) | BRPI0807905A2 (ja) |
CA (1) | CA2678675A1 (ja) |
CL (1) | CL2008000610A1 (ja) |
GB (1) | GB2447015A (ja) |
MX (1) | MX2009009133A (ja) |
PE (1) | PE20081874A1 (ja) |
TW (1) | TW200836738A (ja) |
WO (1) | WO2008104737A1 (ja) |
ZA (1) | ZA200905691B (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2577390T3 (es) | 2006-07-21 | 2016-07-14 | Biodelivery Sciences International, Inc. | Dispositivos de administración transmucosa con mayor captación |
CA2728912C (en) * | 2008-06-23 | 2018-04-10 | Biodelivery Sciences International, Inc. | Multidirectional mucosal delivery devices and methods of use |
US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
CA2845634C (en) | 2011-08-18 | 2021-07-13 | Biodelivery Sciences International, Inc. | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
EP3939569A1 (en) | 2011-09-19 | 2022-01-19 | Orexo AB | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
US20140275148A1 (en) * | 2013-03-15 | 2014-09-18 | Novus Pharma LLC | Orally administrable, self-supporting dissolving film dosage forms |
CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
RU2020112530A (ru) | 2014-03-14 | 2021-07-21 | ОПИАНТ ФАРМАСЮТИКАЛС, Инк. | Назальные готовые лекарственные формы и способы их применения |
US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60146824A (ja) * | 1983-12-06 | 1985-08-02 | レキツト アンド コールマン プロダクツ リミテツド | 鎮痛用組成物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
CN1204890C (zh) * | 1997-12-22 | 2005-06-08 | 欧罗赛铁克股份有限公司 | 防止阿片样物质滥用的方法 |
AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
DK1526848T3 (da) * | 2002-08-09 | 2007-10-22 | Gruenenthal Gmbh | Opiod-receptorantagonister i transdermale systemer med buprenorphin |
US20050191340A1 (en) * | 2002-08-09 | 2005-09-01 | Gruenenthal Gmbh | Opioid-receptor antagonists in transdermal systems having buprenorphine |
EP1584335A3 (en) * | 2004-04-05 | 2006-02-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising a carbinol composition and an opioid |
US8236751B2 (en) * | 2007-03-07 | 2012-08-07 | The Johns Hopkins University | Methods of increasing muscle mass using follistatin-like related gene (FLRG) |
-
2007
- 2007-03-01 GB GB0703967A patent/GB2447015A/en not_active Withdrawn
-
2008
- 2008-02-15 US US12/529,309 patent/US20100168147A1/en not_active Abandoned
- 2008-02-15 KR KR1020097018324A patent/KR20090115863A/ko not_active Application Discontinuation
- 2008-02-15 BR BRPI0807905-6A2A patent/BRPI0807905A2/pt not_active IP Right Cessation
- 2008-02-15 MX MX2009009133A patent/MX2009009133A/es unknown
- 2008-02-15 CN CN2012101207560A patent/CN102670610A/zh active Pending
- 2008-02-15 AU AU2008220573A patent/AU2008220573A1/en not_active Abandoned
- 2008-02-15 WO PCT/GB2008/000523 patent/WO2008104737A1/en active Application Filing
- 2008-02-15 JP JP2009551255A patent/JP2010520185A/ja not_active Ceased
- 2008-02-15 CN CN200880006847A patent/CN101622013A/zh active Pending
- 2008-02-15 CA CA002678675A patent/CA2678675A1/en not_active Abandoned
- 2008-02-15 EP EP08709414A patent/EP2114453A1/en not_active Withdrawn
- 2008-02-27 TW TW097106772A patent/TW200836738A/zh unknown
- 2008-02-28 CL CL200800610A patent/CL2008000610A1/es unknown
- 2008-02-29 PE PE2008000412A patent/PE20081874A1/es not_active Application Discontinuation
- 2008-02-29 AR ARP080100882A patent/AR065581A1/es not_active Application Discontinuation
-
2009
- 2009-08-17 ZA ZA200905691A patent/ZA200905691B/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60146824A (ja) * | 1983-12-06 | 1985-08-02 | レキツト アンド コールマン プロダクツ リミテツド | 鎮痛用組成物 |
Also Published As
Publication number | Publication date |
---|---|
ZA200905691B (en) | 2010-10-27 |
GB2447015A (en) | 2008-09-03 |
PE20081874A1 (es) | 2009-01-26 |
BRPI0807905A2 (pt) | 2014-06-17 |
AR065581A1 (es) | 2009-06-17 |
CL2008000610A1 (es) | 2008-09-05 |
CA2678675A1 (en) | 2008-09-04 |
CN101622013A (zh) | 2010-01-06 |
TW200836738A (en) | 2008-09-16 |
AU2008220573A1 (en) | 2008-09-04 |
EP2114453A1 (en) | 2009-11-11 |
US20100168147A1 (en) | 2010-07-01 |
MX2009009133A (es) | 2009-09-03 |
GB0703967D0 (en) | 2007-04-11 |
KR20090115863A (ko) | 2009-11-09 |
CN102670610A (zh) | 2012-09-19 |
WO2008104737A1 (en) | 2008-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010520185A (ja) | ブプレノルフィンとナロキソンを含む改良医薬組成物 | |
TWI451868B (zh) | 醫藥組成物之改良及相關之改良 | |
JP5577101B2 (ja) | ブプレノルフィンとナルトレキソンを含む改良医薬組成物 | |
CA2661759A1 (en) | Buprenophine-wafer for drug substitution therapy | |
IL149580A (en) | Analgesic preparations containing buprenorphine | |
JP5577102B2 (ja) | ブプレノルフィンとナルメフェンを含む改良医薬組成物 | |
JPWO2008120562A1 (ja) | 帯状疱疹後神経痛治療用錠剤および帯状疱疹後神経痛の治療方法 | |
JP2004043479A (ja) | 経鼻吸収用組成物 | |
AU2014201779A1 (en) | Improved medicinal compositions comprising buprenorphine and naloxone | |
AU2014201777A1 (en) | Improvements in and relating to medicinal compositions | |
AU2014201782A1 (en) | Improved medicinal compositions comprising buprenorphine and naltrexone | |
ZA200203902B (en) | Analgesix compositions containing buprenorphine. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110214 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110214 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20121207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130321 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130620 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130627 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130712 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130722 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130924 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140905 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140912 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20150223 |